All manuscripts
Publications NK Cells G-Rex®6 Well Plate

Inhibition of MICA and MICB Shedding Elicits NK cell–mediated Immunity against Tumors Resistant to Cytotoxic T cells

Published Journal Cancer Immunology Research

Share
26 pages Inhibition of MICA and MICB Shedding Elicits NK cell–mediated Immunity against Tumors Resistant to Cytotoxic T cells — Cancer Immunology Research, 2020

Overview

The study demonstrates that blocking MICA/B shedding enables NK cells to target tumors with MHC-I or IFN-gamma pathway mutations. Human NK cells were expanded in vitro using G-Rex® 6-well plates. This therapeutic strategy effectively reduced metastases in humanized mouse models.

What this paper found

Blocking proteolytic shedding of MICA and MICB with a monoclonal antibody allowed NK cells to attack metastases that cytotoxic T cells cannot control. In mouse lung metastasis models with B16F10 and LLC1 cells expressing human MICA, the 7C6 antibody reduced metastases, including those formed by B2m-knockout or Jak1-knockout cells, and NK-cell depletion removed or reduced this benefit. The antibody was more effective against B2M-knockout than control human A375 melanoma cells in NK-cell killing assays. Combining the antibody with panobinostat (10 mg/kg) raised MICA/B surface levels and reduced lung metastases formed by control A375 cells in NSG mice given human NK cells. Antibody alone reduced metastases from B2M-knockout A375 cells.

Note: The humanized mouse model has limitations, notably limited survival of the transferred human NK cells, which the authors acknowledge.

Induction of NK cell–mediated immunity may thus provide a strategy to treat tumors with escape mutations from T cell–mediated cytotoxicity. — Lucas Ferrari de Andrade, Sushil Kumar, Adrienne Luoma, Yoshinaga Ito, Pedro Henrique Alves da Silva, Deng Pan, Jason W. Pyrdol, Charles H. Yoon, Kai W. Wucherpfennig, Cancer Immunology Research

Study details

Authors
Lucas Ferrari de Andrade, Sushil Kumar, Adrienne Luoma, Yoshinaga Ito, Pedro Henrique Alves da Silva, Deng Pan, Jason W. Pyrdol, Charles H. Yoon, Kai W. Wucherpfennig
Institution
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA · Department of Immunology, Harvard Medical School, Boston, MA, USA · Department of Oncological Sciences and Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA · Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA · Department of Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA
Journal
Cancer Immunology Research
Year
2020
PMID / PMC
PMID: 32209637 · PMC
G-Rex® model(s)
G-Rex®6 Well Plate
Cell type(s)
NK Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

Human NK cells isolated from healthy-donor leukoreduction collars (purity of at least 90%) were expanded in G-Rex® 6-well plates (catalog number 80240M). The culture medium was RPMI-1640 supplemented with 10% FBS, 5% human AB serum, IL2 at 1,000 U/mL and IL15 at 20 ng/mL, and it was replenished once per week. The NK cells were used in experiments between 1 and 3 weeks after isolation. The expanded cells served as effectors in killing assays against A375 melanoma cells and were injected intravenously (1 to 2 × 10^6 cells) into NSG mice for the humanized metastasis model.

Explore related

Full citation

Ferrari de Andrade L, Kumar S, Luoma AM, et al. Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T Cells. Cancer Immunol Res. 2020;8(6):769-780.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →